title: [Preemptive randomized, double-blind study with lornoxicam in gynecological surgery].
abstract: OBJECTIVE
  Lornoxicam is a non opioid analgesic belonging to the oxicam group. The aim of this study was to determine whether lornoxicam has a preemptive analgesic effect.
  
  
  METHODS
  This study was carried out in a randomized, double-blind fashion with 66 patients divided into three groups undergoing gynecological operations. Group I was administered 8 mg of lornoxicam i.v. preoperatively followed by an 8-mg bolus every 8 h for a total dose of 24 mg in the first 24 h. Group II was administered 8 mg of lornoxicam i.v. bolus before the end of the operation followed by 8 mg every 8 h for a total dose of 24 mg in the first 24 h. Group III was administered placebo before and after the operation and for the first 24 h. The effectiveness was assessed postoperatively using the visual analogue scale (at rest, on exertion) and by calculating the total analgesic consumption of morphine hydrochloride in the first 24 h following operation. Vital signs and side effects were documented.
  
  
  RESULTS
  Groups I and II demonstrated significantly reduced pain scores compared to group III at various points in time. Group I also demonstrated a weakly significant reduction in analgesic consumption of morphine hydrochloride postoperatively compared to groups II and III.
  
  
  CONCLUSIONS
  Lornoxicam administered preemptively appears to improve the quality of postoperative analgesia and lead to reduced consumption of opioid analgesics postoperatively in patients undergoing gynecological operations.
authors.affiliation: Abteilung für Anästhesiologie und Intensivmedizin, LKH Klagenfurt, Austria.
authors.forename: E
authors.initials: E
authors.lastname: Trampitsch
authors.forename: W
authors.initials: W
authors.lastname: Pipam
authors.forename: M
authors.initials: M
authors.lastname: Moertl
authors.forename: A
authors.initials: A
authors.lastname: Sadjak
authors.forename: C
authors.initials: C
authors.lastname: Dorn
authors.forename: R
authors.initials: R
authors.lastname: Sittl
authors.forename: R
authors.initials: R
authors.lastname: Likar
mesh_terms: D000328:Adult; D000701:Analgesics, Opioid / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005831:Genital Diseases, Female / Q000601:surgery*; D005833:Genital Neoplasms, Female / Q000601:surgery*; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D009020:Morphine / Q000627:therapeutic use; D010147:Pain Measurement; D010149:Postoperative Pain / Q000517:prevention & control*; D010894:Piroxicam / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011184:Postoperative Period; D011300:Preoperative Care; D013997:Time Factors
chemical_list: D000701:Analgesics, Opioid; D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; D009020:Morphine; C059451:lornoxicam